Aug 17 (Reuters) - AEterna Zentaris Inc:
* Announces results from two phase 3 studies with Cetrorelix in benign
prostatic hyperplasia
* Says tolerability of Cetrorelix in study Z-033 was very good
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces results from two phase 3 studies with Cetrorelix in benign
prostatic hyperplasia
* Says tolerability of Cetrorelix in study Z-033 was very good
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.